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Arteriosclerosis is the basis of all cardiovascular diseases. Numerous risk factors lead 
to the rise of malignant and cardiovascular diseases. Those are: elevated artery blood 
pressure, raised plasma cholesterol and triglycerides, low level of HDL-cholesterol, 
smoking, diabetes mellitus, diet, lack of physical exercises, heredity, stress, gender.  
The aim of the study was to compare the lipid status of patients with cardiovascular 
disease or malignancy. 
The database of the biochemical laboratory and Oncology Counselling Unit of the 
"Ostrog Clinic" was used. The method of random sampling was used and patients (n=29) 
of both genders were selected, aged 40 to 47 years, with cardiovascular diseases, and had 
significant occlusive coronary disease, which required operation or surgical 
revascularization procedure. The patients were classified in two groups: G1 (n=14) with 
statin therapy and G2 (n=15) without statin therapy. Both groups were statistically 
compared with a group of female patients (n=30) with breast cancer, who were between 
37 and 69 years of age. Control group comprised 25 healthy subjects. Standard statistical 
methods were used for processing the lipid status parameters: the arithmetic mean, 
standard deviation SDn and SDn-1, correlation coefficient, post hock test and a single 
factor analysis of  variance. 
The results obtained pointed to the existence of a marked hyperlipoproteinemia type 4 
in the group of cardiovascular patients who did not use statin (G2). In G2, there were 
higher levels of cholesterol, LDL-cholesterol and plasma triglycerides in comparison with 
the control and G1, while the value of HDL-cholesterol was within the range of referent 
values. The obvious suppressing effect of statin on cholesterol and LDL-cholesterol was 
observed in G1. Group G3 had, in comparison with the control and cardiovascular patients, 
significantly lower levels of cholesterol and triglycerides in plasma, as well as lower index 
of atherosclerosis and lower risk factors for the development of atherosclerosis. 
Elevated levels of cholesterol, LDL-C and LDL/HDL-C are the important risk factors for 
atherosclerosis development. These lipids’ risk factors could be modified, especially in the 
primary prevention of cardiovascular diseases. Lower values of lipid parameters in patients 
with malignancy compared to patients with cardiovascular diseases indicated possible 
lower risk for malignancy in these patients. Acta Medica Medianae 2008;47(4):20-23. 
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Introduction 
 
Atheroslerosis lies at the basis of cardio-
vascular diseases. Risk factors leading to the 
development of malignant and cardiovascular 
diseases are numerous. On the basis of anamnestic 
studies in our country (1) and abroad (2,3,4), the 
following are meant to be the risk factors: 
Artery blood pressure - elevated levels of 
artery blood pressure are associated with 
progressive risk increase of coronary disease 
development. The reduction in diastolic blood 
pressure by only 7.5 mmHg reduces the risk of 
coronary disease by 28% and the risk of 
cerebrovascular disease by 44%. 
•  Cholesterol – the connection between a 
coronary disease and the level of plasma 
cholesterol is continuously graded. The risk is 
the highest in the middle age and relatively 
decreases with the aging of men and 
increases with the aging of women. 
•  Triglycerides – elevated levels of triglycerides 
in plasma, especially if linked with lower HDL 
levels, constitute a high risk factor for the 
development of a coronary  disease. 
•  HDL is hereditary, independent and strong 
risk factor for coronary diseases; lower HDL 
levels are associated with high risk. 
•  Smoking – directly associated with the risk 
for coronary disease development. 
•  Diabetes mellitus – associated with excessive 
risk for the development of coronary disease. 
•  Diet – diet rich in saturated fats and 
cholesterol is a great risk factor – obesity is 
an independent  risk factor. 
•  Physical inactivity – relationship inversely 
proportionate to the development of a 
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•  Inheritance-familial susceptibility. 
•  Stress. 
•  Gender – women are less likely to suffer and die 
from the disease in pre-menopause period which 
is explained by the protective role of estrogen. 
On the basis of case-control studies carried 
out abroad and in this country and the 
above-mentioned data, the following common 
risk factors for malignant and cardiovascular 
diseases have been drawn up (5) (Table 1). 
 
Table 1. Common risk factors for malignant neoplasms 
and cardiovascular diseases (5) 
 
Relative risk  Interval of 
confidence 
Common 
risk factors 
MN KVO  MN  KVO 
Age  Increase with aging  5.0-0.8 4.9-8.1 
Smoking  10.1 9.8  7.3-11.  8.0-10.7 
Alcohol  2.9 9.8  1.9-5.0 - 
Diet (lipids)  6.2 7.1  4.0-7.0  5.8-9.8 
Hormones  5.3 -  3.07.0  5.8-9.6 
Infection  3.1 -  -  - 
Immunology  2.9 -  0.8-4.2  - 
Drugs  3.1 -  2.0-9.0  - 
Hereditary  3.6 3.7  1.9-6.0  2.9-5.6 
Stress  1.9 2.3  0.8-6.0  1.2-5.9 
Fatness level  2.8 3.1  1.4-5.2  1.9-4.7 
Exercise level  3.1 3.8  1.6-4.8  1.3-5.9 
Radiation  5.6 -  4.0-11.0  - 
 
Aims  
 
The aim of the paper was to compare the 
lipid status of patients with cardiovascular and 
malignant disease. 
 
Material and methods 
 
The database of the biochemical laboratory 
and the Oncology Counselling Unit of the "Ostrog 
Clinic" was used. The method of random sampling 
was used, and the patients (n=29) of both genders 
were selected, aged 40 to 47, with cardiovascular 
diseases (CVD) – namely, with significant occlu-
sive coronary disease, which required an operation 
or surgical revascularization procedure. The 
patients were classified in two groups: G1 (n=14) 
with statin therapy and G2 (n=15) without statin 
therapy. Both groups were statistically compared 
with a group of female patients (n=30) with 
breast cancer, who were between 37 and 69 
years of age. Control group comprised 25 healthy 
individuals. 
The lipid status parameters were 
determined on the biochemistry analyzer “Hitachi 
902” using the following methods: Cholesterol 
(6), HDL-cholesterol (direct) (7), LDL-cholesterol 
(direct), CHOD-PAP method reagent “Bioanalytica”, 
triglycerides GPO-PAP reagent “Bioanalytica”, 
total lipids method with sulfovanillin acid (8), risk 
factors and atherosclerosis index are calculated 
by the following formula: Atherosclerosis index = 
LDL-C/HDL Chol; Risk factor=Cholesterol/HDL-C. 
Standard statistical methods were used for 
processing the lipid status parameters, namely: 
the arithmetic mean, standard deviation SDn and 
SDn-1, correlation coefficient, post hock test and 
a single factor analysis of variance. 
 
Results 
 
General characteristics of examined patients 
are shown in Table 2. 
 
Table 2. General characteristics of examined patients   
 
 
women 
n(%) 
men 
n(%) 
age (year) 
(x±SD) 
control  20 5  52±4 
Group 1  8 6  57±6 
Group 2  10 5  59±7 
Group 3  30* 0  50±4 
*p<0.05 vs. other groups 
 
Women were more frequent in the group 
with breast malignancy compared to groups with 
cardiovascular patients (p<0.05). There was not 
statistical significance in average age between 
groups. 
The paper compared the lipid status 
parameters of the group of patients with 
cardiovascular diseases (G1 with statin therapy 
and G2 without statin therapy) with a group of 
patients with breast carcinoma (G3) (Table 3). 
In G2 group compared to control, higher 
level of cholesterol (p<0.01), LDL-C (p<0.05) and 
triglicerids in plasma were obtained (p<0.01), 
while concentration of HDL-C was within normal 
range. Group G3 compared to control had lower 
cholesterol (p<0.01) and trigliceride (p<0.01) conce-
ntration. Total lipids were significantly higher in 
patients with cardiovascular diseases (p<0.01). 
 
Table 3. Lipid status parameters  
 
 
Cholesterol (mmol/L) 
HDL-C 
(mmol/L) 
LDL-C  
(mmol/L) 
Total lipids 
(g/L) 
Triglicerids 
control  4.7±0.6 1.3±0.14 2.5±0.8 5.6±1.2 1.2±1 
Group 1  4.41±0.66&& 1.20±0.17  2.45±0.40&&  7.21±1.37**&  1.79±1.02&& 
Group 2  5.99±1.21** 1.46±0.14  3.29±0.92*  10.14±2.08**  3.19±1.52* 
Group 3  3.47±0.59** 1.08±0.20  3.03±0.57  5.64±0.97  0.96±0.36** 
*p<0.05; **p<0.01 vs control; &p<0.05, &&p<0.01 vs. G2 
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The single-factor analysis of variance 
showed that the type of disease has considerable 
effect on the difference in lipid status between 
groups G2 and G3. In the group of cardiovascular 
patients, statins significantly reduced the total 
cholesterol, LDL cholesterol, triglycerides 
(p<0.01) and total lipids concentration (p<0.05) 
(Table 3).  
Atherogenic indexes are shown in Table 4. 
 
Table 4. Atherogenic indexes   
 
 
index of 
atherosclerosis 
risk factor 
control  2.1±0.3 2.53±0.6 
Group 1  2.08±0.40 3.92±0.62**&& 
Group 2  2.16±0.51 4.09±0.69**&& 
Group 3  1.77±0.29* 1.90±0.83* 
*p<0.05, **p<0.01 vs. control; &&p<0.01 vs. G3 
 
Group G3 had, in comparison with control 
and cardiovascular patients, significantly lower 
index of atherosclerosis and lower risk factor for 
the development of atherosclerosis (p<0.05, 
p<0.01, prospectively). Risk factor was 
significantly higher in G1 and G2 group compared 
to control (p<0.01) (Table 4). 
The results obtained pointed to the 
existence of a marked hyperlipoproteinemia 
(HLP) type 4 in the group of cardiovascular 
patients not using statin (G2). 
 
Discussion 
 
It is well-known that hyperlipoproteinemia 
(HLP) is one of the causes leading to the 
development of cardiovascular diseases (9, 10, 
11). This fact has been confirmed by the results 
obtained in this paper. HLP IV is present in the  
group of patients with cardiovascular disease not 
using statin. The same type of HLP was shared by 
the G1 patients before they started with statin 
therapy. 
By correlating patients with cardiovascular 
diseases and those with breast cancer, the 
confounding factor of interference of other 
elements (12) was expressed.  
Accroding to some authors (1, 13, 14), the 
lipid status is a protective factor against 
malignant diseases and the results obtained in 
this paper are in correlation with it. These results 
might correspond to a hypothesis that chronic 
cardiovascular patients suffer less from 
carcinoma in comparison with the rest of the 
patents' population. Other authors (15,16) also 
point to these facts.  Some publications (17,18) 
state that one of the most important common 
risk factors for cardiovascular diseases is age 
(every 10 years there is an arithmetic 
progression of tumour). Our group of patients 
with cardiovascular diseases, aged between 40 
and 70, was small to be divided in 10-year 
periods and to correspond to the statements of 
the authors (17,18). 
On the basis of the results obtained and the 
epidemiological researches of the Oncology 
Counselling Unit of the Ostrog Clinic, we may 
conclude that chronic cardiovascular patients 
suffer 10 to 15 times less from malignant 
diseases. 
The reason, inter alia, may be angiostatin 
and endostatin from the endothelium of blood 
vessels of cardiovascular patients that prevent 
primary vascularisation of the initial group of 
formed malignant cells (17,18). 
 
Conclusion 
 
The results show that lipids’ risk factors for 
atherosclerosis could be modified by statins 
therapy, especially in the primary prevention of 
cardiovascular diseases. 
Elevated levels of cholesterol, LDL-
cholesterol as well as elevated LDL/HDL ratio are 
significant risk factors for the development of 
atherosclerosis as well as for the assessment of 
atherogenic risks of lipid origin. 
Patients with breast malignancy had lower 
values of lipid parameters compared to 
cardiovascular patients and controls which 
indicated somewhat lower risk for malignancies in 
these patients. 
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RAZLIKE U NIVOIMA LIPIDNOG STATUSA KOD BOLESNIKA SA 
ISHEMIJSKIM BOLESTIMA SRCA I MALIGNIH OBOLJENJA 
 
Beretka Atila, Branislava Brkić, Miodrag Đorđević
 i Dragan Zečević 
 
 
  U osnovi kardiovaskularnih oboljenja stoji arterioskleroza. Faktori rizika za nastanak 
malignih oboljenja i kardiovaskularnih oboljenja su brojni. Tu spadaju: povišene vrednosti 
arterijskog krvnog pritiska, povišen holesterol i trigliceridi u plazmi, nizak nivo HDL-
holesterola, pušenje, šećerna bolest, način ishrane, fizička neaktivnost, nasleđe, stres, pol. 
  Cilj rada bio je upoređivanje lipidnih faktora rizika kod kardiovaskularnih i malignih 
bolesnika. 
  Korišćena je baza podataka biohemijske laboratorije i onkološkog savetovališta bolnice 
"Ostrog". Metodom slučajnog uzorka izabrani su bolesnici (n=29) oba pola, starosne dobi 
40-47 godina, sa kardiovaskularnim oboljenjima (KVB) - koji su imali značajnu koronarnu 
okluzivnu bolest, koja je zahtevala interventnu kardiološku ili kardiohiruršku 
revaskularizacionu proceduru. Ovi bolesnici su podeljeni u dve grupe: G1 (n=14) na 
terapiji statinima i G2 (n=15) bez terapije statinima. Obe grupe su statistički poređene sa 
grupom bolesnica (n=30) koje su imale karcinom dojke, starosne dobi 37-69 godina. 
Kontrolu je činilo 25 zdravih ispitanika. Za obradu parametara lipidnog statusa korišćene 
su standardne statističke metode: aritmetička sredina, standardna devijacija SDn i  SDn-1, 
koeficijent korelacije R, post hok test i jedenofaktorska analiza varijanse. 
  Analizom dobijenih rezultata zapaža se izražena hiperlipoproteinemija (HLP) tip IV u 
grupi kardiovaskularnih bolesnika (KVB) koji nisu koristili statine (G2). U ovoj grupi 
nađene su povećane vrednosti holesterola, LDL-holesterola i triglicerida u plazmi, dok je 
vrednost HDL-holesterola bila u opsegu referentnih raspona. U G1 grupi evidentno je 
suprimirajuće dejstvo statina na koncentraciju holesterola i LDL-holesterola. Grupa G3 
imala je, u odnosu na kontrolu i kardiovaskularne bolesnike, izrazito snižene vrednosti 
holesterola i triglicerida u plazmi, kao i smanjene vrednosti indeksa arterioskleroze. 
  Povećani nivoi holesterola, LDL-holesterola, kao i povišen odnos LDL/HDL, značajni su 
faktori rizika za nastanak ateroskleroze, kao i za procenu aterogenog rizika lipidnog 
porekla. Na ove faktore se može uspešno uticati primenom statina, posebno u primarnoj 
prevenciji kardiovaskularnih oboljenja. Niže vrednosti lipidnih pokazatelja kod bolesnika sa 
karcinomom u odnosu na kardiovaskularne bolesnike može ukazivati na nešto manji rizik 
za pojavu malignih oboljenja kod u ovih bolesnika. Acta Medica Medianae 2008;47(4):20-23. 
 
Ključne reči: lipidni status, kardiovaskularna oboljenja, faktori rizika, maligna oboljenja 